閉場中RVOL 0.2xDV $753,66020日平均DV $4M?
Earnings 2026-11-0552W high -46.7%52W low +9.8%Market cap $210MAvg volume 175K
Company Overview
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | -3.50 | $97,000 | -$2M |
| 2026 Q1 | -4.19 | $86,000 | -$4M |
| 2025 Q4 | -7.26 | $130,000 | -$4M |
| 2025 Q3 | -8.50 | $169,000 | -$7M |
| 2025 Q2 | -6.73 | $69,000 | -$11M |
| 2025 Q1 | -10.09 | $202,000 | -$11M |
|
